このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

HTG Molecular Diagnostics マネジメント

マネジメント基準チェック /24

HTG Molecular Diagnostics'の CEO はJohn Lubniewskiで、 Apr2018年に任命され、の在任期間は 6.17年です。の年間総報酬は$ 913.89Kで、 58.9%給与と41.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.053%を直接所有しており、その価値は$ 2.94 。経営陣と取締役会の平均在任期間はそれぞれ8.2年と5.2年です。

主要情報

John Lubniewski

最高経営責任者

US$913.9k

報酬総額

CEO給与比率	58.9%
CEO在任期間	6.2yrs
CEOの所有権	0.05%
経営陣の平均在職期間	8.2yrs
取締役会の平均在任期間	5.2yrs

経営陣の近況

Recent updates

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

Mar 26

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 20

HTG shares surge after upbeat 2020 revenue forecast

Jan 05

HTG Molecular Diagnostics announced 1:15 reverse stock split

Nov 23

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

Nov 18

CEO報酬分析

HTG Molecular Diagnostics の収益と比較して、John Lubniewski の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$914k	US$538k	-US$22m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$737k	US$460k	-US$17m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$1m	US$416k	-US$21m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$384k	-US$19m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$1m	US$327k	-US$16m
Sep 30 2018	n/a	n/a	-US$16m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$691k	US$307k	-US$19m

報酬と市場: Johnの総報酬 ($USD 913.89K ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Johnの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

John Lubniewski (60 yo)

6.2yrs

在職期間

US$913,891

報酬

Mr. John L. Lubniewski serves as President of HTG Molecular Diagnostics, Inc. since April 16, 2018 and also serves as its Chief Executive Officer since April 2019. Mr. Lubniewski served as Chief Operating...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
John Lubniewski	President	6.2yrs	US$913.89k	0.053% $ 1.8
Shaun McMeans	Senior VP	12.3yrs	US$580.32k	0.040% $ 1.3
Laura Godlewski	Senior Vice President of Finance & Administration	2.4yrs	データなし	0.018% $ 0.6
Debra Gordon	Senior VP & Chief Legal Counsel	13yrs	US$296.70k	データなし
Patrick Roche	Senior Vice President of Research & Development	10.2yrs	US$507.38k	データなし
Stephen Barat	Senior Vice President of Therapeutics	2.7yrs	データなし	0.019% $ 0.6
Christina Carruthers	Vice President of Target Strategy & Early Development	no data	データなし	データなし
Debrah Thompson	Vice President of Scientific Innovation	no data	データなし	データなし

8.2yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: HTGM.Qの経営陣は経験豊富で経験豊富です（平均在職期間は8.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
John Lubniewski	President	5.2yrs	US$913.89k	0.053% $ 1.8
Michelle Griffin	Independent Director	5.8yrs	US$54.75k	0.00059% $ 0.02
Lee McCracken	Independent Director	8.7yrs	US$49.41k	0.0012% $ 0.04
Ann Hanham	Independent Chairman of the Board	7.8yrs	US$80.05k	0.0018% $ 0.06
Thomas Dubensky	Independent Director	1.8yrs	US$11.00k	データなし
Christopher Kiritsy	Non-Employee Independent Director	2.4yrs	US$53.83k	0% $ 0
Davide Ruggero	Member of Scientific Advisory Board	no data	データなし	データなし
Frank Slack	Member of Scientific Advisory Board	no data	データなし	データなし
Robert Spitale	Member of Therapeutics Scientific Advisory Board	2.3yrs	データなし	データなし
Amir Horowitz	Member of Scientific Advisory Board	no data	データなし	データなし
Mateusz Koptyra	Member of Scientific Advisory Board	no data	データなし	データなし
Kendall Van Keuren-Jensen	Member of Scientific Advisory Board	no data	データなし	データなし

5.2yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: HTGM.Qの取締役会は経験豊富であると考えられます ( 5.2年の平均在任期間)。

HTG Molecular Diagnostics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Announces Board Changes

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Q2 GAAP loss per share widens, revenue down

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$3.25

HTG Molecular Diagnostics amends senior loan facility

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$9.50

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Consensus revenue estimates fall by 16%

Full year 2021 earnings: EPS exceeds analyst expectations

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

HTG Molecular completes product design lock for planned transcriptome panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

Price target decreased to US$9.75

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

Consensus forecasts updated

Price target decreased to US$11.75

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: US$7.83

New 90-day high: US$7.27

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Price target lowered to US$9.25

New 90-day high: US$6.10

HTG shares surge after upbeat 2020 revenue forecast

New 90-day high: US$5.61

Analysts update estimates

HTG Molecular Diagnostics announced 1:15 reverse stock split

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

マネジメント基準チェック /24